Protein Sciences and Passport Health team up on Flublok; MicroVAX begins cancer vax trial;

> Protein Sciences and Passport Health have teamed up to offer the Flublok flu vaccine at more than 230 Passport Health locations across the U.S. Release

> MicroVAX has begun a Phase I trial for its cancer vaccine platform for patients with breast, prostate, colon, ovary and lung cancers that have relapsed after initial therapy. Report

> In a U.K. study, researchers from the University of Southampton found that two new meningitis vaccines, Novartis' Menveo (MenACWY-CRM) and Bexsero (4CMenB), prevented the transmission of meningitis bacteria by up to 40%.

And Finally... Up to 30,000 people could have used experimental treatments or vaccines so far in the world's worst outbreak of Ebola, British scientists say. Report